Analysis of early readmissions after combined pancreas-kidney transplantation

American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
R J StrattaI S Gill

Abstract

Combined pancreas-kidney transplantation (PKT) has become generally accepted as an effective treatment option, but controversy exists regarding the early morbidity rate of the procedure. To address this issue, we retrospectively analyzed all readmissions occurring in the first 3 months after PKT. Over a 5-year period, we performed 98 PKTs with bladder drainage. The mean recipient age was 36.6 years, with a mean pretransplant duration of diabetes of 23.5 years. All patients received quadruple immunosuppression with antilymphocyte induction therapy. The mean length of initial hospital stay was 20 days. One hundred forty-five readmissions occurred in 73 patients (74.5%), with the initial readmission occurring at a mean of 8.5 days after hospital dismissal and 28 days after PKT. Twenty-five patients (25.5%) had no readmissions, 35 (36%) had one readmission, 17 (17%) had two readmissions, and the remaining 21 patients (21.5%) had three or more readmissions in the first 3 months. The mean number of readmissions was 1.5 per patient. Forty-seven patients (48%) were readmitted within 1 week, and all but one initial readmission occurred within 1 month of hospital dismissal. Causes of readmission included rejection (51), infection (32), p...Continue Reading

References

Nov 11, 1992·American Journal of Surgery·C F OzakiB W Shaw
Jan 1, 1987·Transplantation·R MundaJ W Alexander
Jan 1, 1989·Transplantation·J S NajarianD E Sutherland
Sep 1, 1989·Annals of Surgery·D E SutherlandP Morel
Oct 1, 1988·Annals of Surgery·H W SollingerF O Belzer
Feb 1, 1986·Annals of Surgery·U J HesseJ S Najarian
Dec 1, 1993·American Journal of Surgery·R J StrattaB W Shaw
Jun 1, 1995·Annals of Surgery·A O GaberL G Britt
Dec 1, 1994·Annals of Surgery·R J StrattaW C Duckworth
May 1, 1993·Transplantation·R J StrattaA N Langnas
Feb 1, 1995·International Journal of Pancreatology : Official Journal of the International Association of Pancreatology·R J StrattaK Cushing
Mar 1, 1996·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·J D PirschM R Weir

❮ Previous
Next ❯

Citations

Dec 24, 2018·Clinical Transplantation·Melissa Gaspar TavaresJose Osmar Medina Pestana
Mar 31, 2015·European Journal of Gastroenterology & Hepatology·Peixian ChenMingqing Xu
Apr 1, 2020·Jornal brasileiro de nefrologia : ʹorgão oficial de Sociedades Brasileira e Latino-Americana de Nefrologia·Melissa Gaspar TavaresJose Osmar Medina Pestana
Jun 9, 1998·Current Opinion in Nephrology and Hypertension·D E Sutherland
Dec 8, 2004·Endocrine Reviews·Jennifer L Larsen
Oct 17, 2015·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·E A KingD L Segev
Oct 16, 2015·Transplantation·Alvin Ho-ting LiS Joseph Kim
Jun 18, 2016·Clinical Transplantation·Andrew M CourtwrightHilary J Goldberg
Jun 17, 1998·The Journal of Clinical Endocrinology and Metabolism·R P RobertsonS Genuth
Dec 5, 2020·Experimental and Clinical Transplantation : Official Journal of the Middle East Society for Organ Transplantation·Naeem GoussousJoseph R Scalea
Dec 31, 2002·Journal of the American Society of Nephrology : JASN·Sarbjit V JassalDonald A Redelmeier

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cellular Immunometabolism

Immunometabolism involves not only the way metabolites are digested by the immune system, but the way in which they can alter the pathway of the immune system. These responses occur in day-to-day healthy cell functioning, but can result in diseases, such as autoimmune disorders. Discover the latest research on cellular immunometabolism here.

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.